Shanghai, China – April 8, 2018 – Asieris Pharmaceuticals, a clinical stage biopharmaceutical company, announced today that Dr. Kevin Pan,the company CEO, has been invited to attend the Asia Pharma R&D Leaders Summit 2018 ( APRDL 2018, http://aprdl2018.com/) to be held on April 18 at InterContinental Shanghai Pudong Hotel as a panelist in a the “Chinese BioPharma R&D Opportunities in the Future” forum.
About Asieris Pharmaceuticals
Asieris Pharmaceuticals was founded in 2010, and aspires to becoming a China-based biotech company with global impacts. Asieris has business and R&D operations in Shanghai, Beijing, and in China Medical City of Taizhou, Jiangsu Province. Asieris’ multi-disciplinary R&D team with deep technical expertise is led by several experienced “returnees”, with a focus on the discovery and development of innovative drugs to address significant unmet medical needs, such as cancer.
APL-1202, Asieris’ leading drug candidate, has been supported by China’s 12th and 13th “National 5-Year important Innovations” funding programs. Developed from an invention in-licensed from the Johns Hopkins University, APL-1202 has a novel mechanism of action, and currently is the only oral drug in the world under Pivotal Trial for the treatment of non-muscle invasive bladder cancer. Asieris’ APL-1501 has been granted as one of the programs under China’s 13th “National 5-Year important Innovations: Development of drugs and critical technology platforms for the prevention and treatment of multi-drug resistance (MDR)”. In addition to its proprietary drugs, anti-cancer and anti-MDR platforms, Asieris is currently in active negotiation with multiple international pharmaceutical and biotech companies for partnerships in China and global markets.
